The collaboration supports Roche’s plans announced in October 2011 to develop a new line of analyzers for the central coagulation lab, which will be marketed under Roche’s cobas brand.

Roche will also commercialize Technoclone’s range of research use only products which facilitate the needs of specialists and researchers in the hemostasis research community, as part of the agreement.

Roche said the new line of coagulation assays are expected to be launched in the US and Canada in 2014.

Roche Diagnostics marketing vice president Randy Pritchard said the expansion of the reagent menu into key areas of hemostasis will greatly enhance the new line of laboratory coagulation analyzers in development and will open up new opportunities for research related to targeted treatment and personalized healthcare.